Abstract

BackgroundIBC (Inflammatory Breast cancer) is a rare form of breast cancer with a particular phenotype. New molecular targets are needed to improve the treatment of this rapidly fatal disease. Given the role of NF-κB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated in IBC.MethodsWe measured the mRNA expression levels of 60 NF-κB-related genes by using real-time quantitative RT-PCR in a well-defined series of 35 IBCs, by comparison with 22 stage IIB and III non inflammatory breast cancers. Twenty-four distant metastases of breast cancer served as "poor prognosis" breast tumor controls.ResultsThirty-five (58%) of the 60 NF-κB-related genes were significantly upregulated in IBC compared with non IBC. The upregulated genes were NF-κB genes (NFKB1, RELA, IKBKG, NFKBIB, NFKB2, REL, CHUK), apoptosis genes (MCL1L, TNFAIP3/A20, GADD45B, FASLG, MCL1S, IER3L, TNFRSF10B/TRAILR2), immune response genes (CD40, CD48, TNFSF11/RANKL, TNFRSF11A/RANK, CCL2/MCP-1, CD40LG, IL15, GBP1), proliferation genes (CCND2, CCND3, CSF1R, CSF1, SOD2), tumor-promoting genes (CXCL12, SELE, TNC, VCAM1, ICAM1, PLAU/UPA) or angiogenesis genes (PTGS2/COX2, CXCL1/GRO1). Only two of these 35 genes (PTGS2/COX2 and CXCL1/GRO1)were also upregulated in breast cancer metastases. We identified a five-gene molecular signature that matched patient outcomes, consisting of IL8 and VEGF plus three NF-κB-unrelated genes that we had previously identified as prognostic markers in the same series of IBC.ConclusionThe NF-κB pathway appears to play a major role in IBC, possibly contributing to the unusual phenotype and aggressiveness of this form of breast cancer. Some upregulated NF-κB-related genes might serve as novel therapeutic targets in IBC.

Highlights

  • IBC (Inflammatory Breast cancer) is a rare form of breast cancer with a particular phenotype

  • The 35 upregulated genes included NF-κB genes (NFKB1, RELA, IKBKG, NFKBIB, NFKB2, REL, CHUK) and NF-κBregulated genes involved in apoptosis (MCL1L, TNFAIP3/ A20, GADD45B, FASLG, MCL1S, IER3L, TNFRSF10B/ TRAILR2), immune response (CD40, CD48, TNFSF11/ RANKL, TNFRSF11A/RANK, CCL2/MCP-1, CD40LG, IL15, GBP1), proliferation (CCND2, CCND3, CSF1R, CSF1, SOD2), tumor progression (CXCL12, SELE, TNC, VCAM1, ICAM1, PLAU/UPA) or angiogenesis (PTGS2/COX2, CXCL1/GRO1)

  • Two (PTGS2/COX2 and CXCL1/ GRO1) of these 35 genes were upregulated in the metastases relative to the 22 non IBCs (Table 2)

Read more

Summary

Introduction

IBC (Inflammatory Breast cancer) is a rare form of breast cancer with a particular phenotype. The main features distinguishing IBC (Inflammatory Breast Cancer) from other forms of primary breast cancer are a unique phenotype, which includes rapidly progressive breast inflammation, and an extreme tendency to metastasize. We and others have described several molecular alterations in IBC, such as frequent hormone receptor negativity, TP53 mutations and HER2/neu amplification [2,3,4,5]. The expression of some of these genes is altered in human IBC tumors [6]. None of these genetic alterations is specific to the particular phenotype of IBC

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call